ID: ALA4438921

Max Phase: Preclinical

Molecular Formula: C25H24FN5O4

Molecular Weight: 477.50

Molecule Type: Unknown

Representations

Canonical SMILES:  O=C(N/N=C/c1ccc2c(c1)OCO2)c1cn(C2CC2)c2cc(N3CCNCC3)c(F)cc2c1=O

Standard InChI:  InChI=1S/C25H24FN5O4/c26-19-10-17-20(11-21(19)30-7-5-27-6-8-30)31(16-2-3-16)13-18(24(17)32)25(33)29-28-12-15-1-4-22-23(9-15)35-14-34-22/h1,4,9-13,16,27H,2-3,5-8,14H2,(H,29,33)/b28-12+

Standard InChI Key:  ZOPWVCIVTWGJQR-KVSWJAHQSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Unknown

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 477.50

Molecular Weight (Monoisotopic): 477.1812

AlogP: 2.38

#Rotatable Bonds: 5

Polar Surface Area: 97.19

Molecular Species: BASE

HBA: 8

HBD: 2

#RO5 Violations: 0

HBA (Lipinski): 9

HBD (Lipinski): 2

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 11.71

CX Basic pKa: 8.67

CX LogP: 2.51

CX LogD: 1.22

Aromatic Rings: 3

Heavy Atoms: 35

QED Weighted: 0.43

Np Likeness Score: -1.18

References

1. Liang X, Wu Q, Luan S, Yin Z, He C, Yin L, Zou Y, Yuan Z, Li L, Song X, He M, Lv C, Zhang W..  (2019)  A comprehensive review of topoisomerase inhibitors as anticancer agents in the past decade.,  171  [PMID:30917303] [10.1016/j.ejmech.2019.03.034]

2. Gao F, Zhang X, Wang T, Xiao J..  (2019)  Quinolone hybrids and their anti-cancer activities: An overview.,  165  [PMID:30660827] [10.1016/j.ejmech.2019.01.017]

3. Ahadi H, Emami S..  (2020)  Modification of 7-piperazinylquinolone antibacterials to promising anticancer lead compounds: Synthesis and in vitro studies.,  187  [PMID:31881454] [10.1016/j.ejmech.2019.111970]

4. Gao F, Wang P, Yang H, Miao Q, Ma L, Lu G..  (2018)  Recent developments of quinolone-based derivatives and their activities against Escherichia coli.,  157  [PMID:30193220] [10.1016/j.ejmech.2018.08.095]

Source

Source(1):

• Scientific Literature